OCS
NASDAQ
$12.29
Oculis Holding AG (OCS)
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company is headquartered in Zug, Switzerland.
This company is also listed under the following ticker: OCSAW.
Website: https://oculis.comSector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $40.28 (+227.75%)
Market Cap
$1.74B
Free Cash Flow Yield
-4.51%
Beta (5Y)
0.61
Price Chart
Valuation
Market Cap$1.74B
P/S1143.55
P/B7.15
Profitability
Total Revenue (TTM)$631K
Gross Profit (TTM)-$69M
EBITDA-$106M
Operating Margin-5020%
EPS-$2.17
Financial Health
Debt-to-Equity1.1%
Free Cash Flow Yield-4.51%
Growth & Risk
Beta (5Y)0.61
Sharpe Ratio-0.45